Siegfried Reich, PhD is an independent consultant with over 35 years of experience across both pharma (Pfizer and Lilly) and smaller biotech (Agouron, SGX, eFFECTOR, Turning Point) where he served as CSO, co-founder, head of research etc. Siegfried lead the delivery of over 25 development candidates across oncology, ophthalmology, anti-virals and two approved drugs, Viracept and Axitinib, for which he is also a coinventor. He has expertise in drug discovery and development strategy, creating small molecule or biological therapeutics for difficult-to-drug targets through the application of disciplined drug discovery, medicinal chemistry, and structure- and fragment-based chemistry.